Alpha 2-adrenergic receptors of the alpha 2c subtype mediate inhibition of norepinephrine release in human kidney cortex. 1994

A U Trendelenburg, and N Limberger, and L C Rump
Pharmakologisches Institut, Universitätsklinikum, Freiburg, Germany.

The pharmacological properties of the alpha 2-adrenergic receptors regulating the release of norepinephrine were investigated in human kidney cortex. Slices were preincubated with [3H]norepinephrine, superfused in the presence of desipramine, and stimulated electrically. Two procedures were used to estimate the affinity of alpha-adrenergic antagonists at the autoreceptors. First, pEC30 values (negative logarithms of antagonist concentrations that increased the electrically evoked overflow of tritium by 30%) were determined. Second, antagonist pKd values were determined against the overflow-inhibiting effect of the alpha 2 receptor-selective agonist UK 14,304. Antagonist pEC30 values correlated well with the respective pKd values (r = 0.96, p < 0.01). The site of action of the phenylethylamine norepinephrine, as well as of the imidazoline derivative UK 14,304, is an alpha 2-adrenergic receptor. Neither the cyclooxygenase inhibitor indomethacin nor the adenosine receptor antagonist 8-sulfophenyltheophylline changed the concentration-inhibition curve of UK 14,304. When compared with binding data from the literature, the pEC30 values correlated best with the antagonist affinities at alpha 2c binding sites in an opossum kidney cell line and rat brain cortex (r > or = 0.95, p < 0.001) and at the affinities of alpha 2c sites obtained in COS cells transfected with either the human alpha 2-C4 or rat RG10-alpha 2 gene (r > or = 0.95, p < 0.01). In contrast, the correlations with alpha 2A, alpha 2B, and alpha 2D sites were not as good. Moreover, the alpha 2-autoreceptors in human kidney cortex were very similar to the alpha 2C-adrenergic receptors mediating prostaglandin synthesis in rabbit aorta but differed from alpha 2A- and alpha 2D-autoreceptors in rabbit and rat tissues. It is concluded that in human kidney cortex prejunctional autoreceptors are alpha 2C.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007672 Kidney Cortex The outer zone of the KIDNEY, beneath the capsule, consisting of KIDNEY GLOMERULUS; KIDNEY TUBULES, DISTAL; and KIDNEY TUBULES, PROXIMAL. Cortex, Kidney
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D010109 Oxymetazoline A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251) Oxymetazoline Hydrochloride,Hydrochloride, Oxymetazoline
D011810 Quinoxalines Quinoxaline
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068438 Brimonidine Tartrate A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate,5-bromo-6-(imidazolidinylideneamino)quinoxaline,5-bromo-6-(imidazolin-2-ylamino)quinoxaline,AGN 190342,AGN-190342,Alphagan,Alphagan P,Brimonidine,Brimonidine Purite,Brimonidine Tartrate (1:1),Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer,Brimonidine Tartrate, (R-(R*,R*))-Isomer,Bromoxidine,Mirvaso,Ratio-Brimonidine,Sanrosa,UK 14,304,UK 14,304-18,UK 14304,UK 14308,UK-14,304-18,UK-14,308,UK-14304,AGN190342,Ratio Brimonidine,UK 14,304 18,UK 14,30418,UK 14,308,UK14,30418,UK14,308,UK14304
D000316 Adrenergic alpha-Agonists Drugs that selectively bind to and activate alpha adrenergic receptors. Adrenergic alpha-Receptor Agonists,alpha-Adrenergic Receptor Agonists,Adrenergic alpha-Agonist,Adrenergic alpha-Receptor Agonist,Receptor Agonists, Adrenergic alpha,Receptor Agonists, alpha-Adrenergic,alpha-Adrenergic Agonist,alpha-Adrenergic Agonists,alpha-Adrenergic Receptor Agonist,Adrenergic alpha Agonist,Adrenergic alpha Agonists,Adrenergic alpha Receptor Agonist,Adrenergic alpha Receptor Agonists,Agonist, Adrenergic alpha-Receptor,Agonist, alpha-Adrenergic,Agonist, alpha-Adrenergic Receptor,Agonists, Adrenergic alpha-Receptor,Agonists, alpha-Adrenergic,Agonists, alpha-Adrenergic Receptor,Receptor Agonist, alpha-Adrenergic,Receptor Agonists, alpha Adrenergic,alpha Adrenergic Agonist,alpha Adrenergic Agonists,alpha Adrenergic Receptor Agonist,alpha Adrenergic Receptor Agonists,alpha-Agonist, Adrenergic,alpha-Agonists, Adrenergic,alpha-Receptor Agonist, Adrenergic,alpha-Receptor Agonists, Adrenergic

Related Publications

A U Trendelenburg, and N Limberger, and L C Rump
January 2002, The Journal of pharmacology and experimental therapeutics,
A U Trendelenburg, and N Limberger, and L C Rump
May 1997, The Journal of pharmacology and experimental therapeutics,
A U Trendelenburg, and N Limberger, and L C Rump
January 1995, Life sciences,
A U Trendelenburg, and N Limberger, and L C Rump
February 1994, Experimental eye research,
A U Trendelenburg, and N Limberger, and L C Rump
June 1987, Brain research,
A U Trendelenburg, and N Limberger, and L C Rump
June 1987, Hypertension (Dallas, Tex. : 1979),
A U Trendelenburg, and N Limberger, and L C Rump
October 1991, The Journal of pharmacology and experimental therapeutics,
A U Trendelenburg, and N Limberger, and L C Rump
January 2002, Uspekhi fiziologicheskikh nauk,
Copied contents to your clipboard!